NasdaqGS:CGONBiotechs
How Higher Losses and Escalating Expenses at CG Oncology (CGON) Have Changed Its Investment Story
CG Oncology, Inc. announced earnings results for the second quarter and first half of 2025, reporting a net loss of US$41.43 million for the quarter and US$75.88 million for the six months ended June 30, both sharply higher than a year earlier.
The company's basic loss per share from continuing operations also increased substantially, highlighting escalating expenses or investment as a key theme in its financial performance.
We'll explore how the increased net loss and rising loss per share...